$GMED earnings report

Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program. AlphAI read Globus Medical's Third quarter 2026 filing as mixed. 2 quarters are on record below.

Third quarter 2026

AlphAI · Earnings readGMED · Third quarter 2026 · ended September 30, 2026

Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program

→Mixed quarter

Third-quarter net sales declined 0.7% as reported and full-year revenue guidance was reduced to $3.09 billion from $3.18 billion to $3.22 billion, while gross margins, GAAP earnings, operating cash flow and free cash flow improved and the Board authorized an additional $500 million for repurchases.

Revenue
$764M
(0.7%) y/y
Musculoskeletal Solutions, three months ended September 30, 2026
$729M
EPS · non-GAAP
$1.23
4.4% y/y
Full-year fiscal 2026 outlook
$3.09 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, three months ended September 30, 2026GAAP$763.7M–(0.7%)
Net sales, nine months ended September 30, 2026GAAP$2.31B–9.5%
Base business net sales, three months ended September 30, 2026non-GAAP$690.0M–3.0%
Nevro products net sales, three months ended September 30, 2026other$73.70M––
Base business net sales, nine months ended September 30, 2026non-GAAP$2.08B––
Nevro products net sales, nine months ended September 30, 2026other$237.4M––
Cost of sales, three months ended September 30, 2026GAAP$232.9M––
Research and development expense, three months ended September 30, 2026GAAP$34.53M––
Selling, general and administrative expense, three months ended September 30, 2026GAAP$288.5M––
Amortization of intangibles, three months ended September 30, 2026GAAP$29.57M––
Acquisition-related costs, three months ended September 30, 2026GAAP$720K––
Restructuring costs, three months ended September 30, 2026GAAP−$43K––
Gross profit, three months ended September 30, 2026GAAP$509.2M––
Gross profit as a percentage of net sales, three months ended September 30, 2026GAAP66.7%–an increase of 2.5%
Adjusted gross profit, three months ended September 30, 2026non-GAAP$530.8M––
Adjusted gross profit as a percentage of net sales, three months ended September 30, 2026non-GAAP69.5%–an increase of 1.4%
Operating income, three months ended September 30, 2026GAAP$177.6M––
Income before income taxes, three months ended September 30, 2026GAAP$183.3M––
Income tax provision, three months ended September 30, 2026GAAP$42.10M––
Net income, three months ended September 30, 2026GAAP$141.2M–18.7%
Net income as a percentage of net sales, three months ended September 30, 2026GAAP18.5%––
Diluted earnings per share, three months ended September 30, 2026GAAP$1.04–18.2%
Non-GAAP net income, three months ended September 30, 2026non-GAAP$167.0M––
Non-GAAP diluted earnings per share, three months ended September 30, 2026non-GAAP$1.23–4.4%
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$262.2M––
Adjusted EBITDA as a percentage of net sales, three months ended September 30, 2026non-GAAP34.3%––
Operating income, nine months ended September 30, 2026GAAP$510.4M––
Net income, nine months ended September 30, 2026GAAP$417.0M––
Diluted earnings per share, nine months ended September 30, 2026GAAP$3.04––
Non-GAAP net income, nine months ended September 30, 2026non-GAAP$506.2M––
Non-GAAP diluted earnings per share, nine months ended September 30, 2026non-GAAP$3.69––
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP$787.3M––
Net cash provided by operating activities, three months ended September 30, 2026GAAP$265.2M––
Free cash flow, three months ended September 30, 2026non-GAAP$224.8M––
Net cash provided by operating activities, nine months ended September 30, 2026GAAP$677.3M––
Purchases of property and equipment, nine months ended September 30, 2026GAAP−$113.2M––
Free cash flow, nine months ended September 30, 2026non-GAAP$564.2M––

Segments

SegmentRevenueq/qy/y
Musculoskeletal Solutions, three months ended September 30, 2026No product-category growth driver was provided.$728.9M––
Enabling Technologies, three months ended September 30, 2026The Company said it deployed 73% more robot and navigation units as compared to the prior year quarter.$34.86M–24%
United States net sales, three months ended September 30, 2026U.S. Spine faced difficult prior year comparables and grew 2% in the third quarter, according to the Chief Executive Officer.$621.0M–0.5%
International net sales, three months ended September 30, 2026International net sales decreased 5.0% on a constant currency basis.$142.7M–(5.7%)

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full-year fiscal 2026 outlook

  • Revenue$3.09 billion
  • NoteNon-GAAP fully diluted EPS: $4.95 to $5.05
  • NoteRevenue growth as compared to fiscal 2025: 5.1%
  • NoteGrowth over fiscal 2025 non-GAAP fully diluted EPS: 24.4% to 26.9%

Capital returns

  • On November 2, 2026, the Board of Directors authorized an additional $500 million of common-stock repurchases under the existing Repurchase Program.
  • The Repurchase Program does not have an expiration date.
  • Repurchase of common stock for the nine months ended September 30, 2026 was $(279,001), compared with $(255,451) for the nine months ended September 30, 2025.

What drove it

  • Base business sales, excluding Nevro, were $690.0 million and increased 3.0%, as reported.
  • Enabling Technologies delivered revenue growth of 24%.
  • Cost of sales decreased $19.6 million and operating expenses decreased $25.9 million in comparison to the third quarter of 2025, which the Company identified as the primary drivers of GAAP net income growth.
  • Adjusted gross profit margin expanded to 69.5% from 68.1% in the prior-year quarter.
  • The Company said this was the eighth straight quarter of sequential adjusted gross profit margin expansion.

Concerns

  • Worldwide net sales decreased 0.7% as reported and decreased 0.5% on a constant currency basis.
  • International net sales decreased 5.7% as reported and decreased 5.0% on a constant currency basis.
  • Nevro products net sales were $73,701 for the third quarter of 2026, compared with $99,254 for the third quarter of 2025.
  • Full-year 2026 revenue guidance was updated to $3.09 billion from the previous range of $3.18 billion to $3.22 billion.
  • U.S. Spine grew 2% in the third quarter against difficult prior-year comparables, according to the Chief Executive Officer.

What to watch

  • Execution against full-year fiscal 2026 revenue guidance of $3.09 billion.
  • The trajectory of U.S. Spine sales following 2% third-quarter growth and difficult prior-year comparables.
  • International sales performance after a 5.7% as-reported decline and a 5.0% constant-currency decline.
  • Nevro product sales following third-quarter net sales of $73,701.
  • Whether adjusted gross profit margin continues its sequential expansion trend.
  • The timing and actual number of shares repurchased under the expanded Repurchase Program.

Balance sheet and cash flow

  • Cash and cash equivalents were $441,272 at September 30, 2026, compared with $526,156 at December 31, 2025.
  • Short-term marketable securities were $76,163 and long-term marketable securities were $353,738 at September 30, 2026.
  • Total cash, cash equivalents and marketable securities were $871,173 at September 30, 2026, compared with $629,062 at December 31, 2025.
  • Total assets were $5,528,193, total liabilities were $731,943, and total equity was $4,796,250 at September 30, 2026.
  • Inventories were $824,144 at September 30, 2026, compared with $759,277 at December 31, 2025.
  • Cash, cash equivalents, and restricted cash at end of period were $487,687 at September 30, 2026, compared with $371,769 at September 30, 2025.

Analysis

Globus Medical reported third-quarter net sales of $763,719, down 0.7% from $769,048 in the prior-year period. U.S. net sales increased 0.5% to $620,980, while international net sales fell 5.7% to $142,739, or 5.0% on a constant currency basis. Base business sales were $690,018, up 3.0%, but Nevro product sales were $73,701 versus $99,254. The Chief Executive Officer described difficult U.S. Spine comparisons and said U.S. Spine grew 2%.

Profitability improved materially despite the sales decline. GAAP gross profit margin was 66.7%, compared with 64.2%, and non-GAAP adjusted gross profit margin was 69.5%, compared with 68.1%. Cost of sales was $232,917 versus $252,533, while selling, general and administrative expense was $288,471 versus $313,597. Operating income rose to $177,551 from $137,363, and GAAP net income increased to $141,171 from $118,966. GAAP diluted EPS was $1.04 versus $0.88, while non-GAAP diluted EPS was $1.23 versus $1.18.

Cash generation remained strong. Third-quarter operating cash flow was $265,227 and free cash flow was $224,838, compared with $249,696 and $213,879, respectively. For the nine months ended September 30, 2026, operating cash flow was $677,332 and free cash flow was $564,160. The Company held $871,173 of total cash, cash equivalents and marketable securities at September 30, 2026. It also repurchased $279,001 of common stock during the first nine months and received authorization for an additional $500 million under its existing repurchase program.

The outlook is the principal offset to the stronger margins and cash flow. Globus updated full-year 2026 revenue guidance to $3.09 billion from the previous range of $3.18 billion to $3.22 billion, while reaffirming non-GAAP fully diluted EPS guidance of $4.95 to $5.05. The revised revenue target represents 5.1% growth as compared to fiscal 2025, and the EPS range represents 24.4% to 26.9% growth over fiscal 2025 non-GAAP fully diluted EPS. Investors should focus on the revenue reset, international demand, Nevro sales, and whether margin expansion and free cash flow remain durable while the Company executes its technology deployment strategy.

Management, verbatim

Third quarter revenue finished at $764 million, down slightly from the prior year quarter.

Keith Pfeil, President and Chief Executive Officer

Our Enabling Technologies strategy continued to make progress, delivering revenue growth of 24%, while simultaneously deploying 73% more robot and navigation units as compared to the prior year quarter, reflecting continued strong demand for our technology and execution against our capital deployment plan.

Keith Pfeil, President and Chief Executive Officer

Our third quarter results highlight our Company’s commitment to delivering consistent adjusted gross profit margin expansion, bottom-line profit, and free cash flow generation, as we delivered the eighth straight quarter of sequential adjusted gross profit margin expansion and record quarterly operating cash flow and free cash flow generation.

Kyle Kline, Chief Financial Officer

Not in the filing

stated, not guessed
  • Previous-release outlook was not provided, so comparison of actual results with prior guidance is unavailable.
  • Prior-quarter figures and sequential changes were not reported for the listed key metrics.
  • Full-year fiscal 2026 guidance for gross margin, operating expenses, tax rate, operating cash flow and free cash flow was not provided.
  • A GAAP or non-GAAP effective tax rate was not reported.
  • Debt balances were not reported as a balance-sheet line item.
  • Product-category year-over-year changes for Musculoskeletal Solutions were not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readGMED · Second Quarter 2026 · ended June 30, 2026

Globus Medical reported 5.9% worldwide net-sales growth and raised full-year non-GAAP fully diluted EPS guidance.

✓Solid quarter

Worldwide net sales increased 5.9%, non-GAAP diluted EPS increased 55.8%, and the Company raised non-GAAP fully diluted EPS guidance while reaffirming revenue guidance. GAAP net income and GAAP diluted EPS declined because the prior-year quarter included a $110.5 million bargain purchase gain related to the Nevro acquisition.

Revenue
$790M
5.9% y/y
EPS · non-GAAP
$1.34
55.8% y/y
Full-year 2026 outlook
$3.18 billion to $3.22 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Worldwide net salesGAAP$789.6M–5.9%
Worldwide net sales growth, constant currencyother5.6%–5.6%
U.S. net sales growthGAAP3.0%–3.0%
International net sales growth, as reportedGAAP18.0%–18.0%
International net sales growth, constant currencyother16.2%–16.2%
GAAP net incomeGAAP$151.6M–(25.3%)
GAAP diluted EPSGAAP$1.10–(26.2%)
Non-GAAP diluted EPSnon-GAAP$1.34–55.8%
Adjusted gross margin expansionnon-GAAP200 basis points–200 basis points
Base business revenue growth excluding Nevroother9%––
US Spine growthother7%––
International Spine growth, as reportedother14%––
International Spine growth, constant currencyother12%––

Full-year 2026 outlook

  • Revenue$3.18 billion to $3.22 billion
  • NoteNon-GAAP fully diluted EPS: $4.95 to $5.05
  • NotePrevious non-GAAP fully diluted EPS range: $4.70 to $4.80

What drove it

  • Share gains across a majority of underlying businesses.
  • US Spine grew 7%.
  • International Spine grew 14% as-reported and 12% on a constant currency basis.
  • Adjusted gross margin expanded 200 basis points compared to the second quarter of the prior year.
  • The Company cited margin expansion, operating leverage, and synergy realization.

Concerns

  • GAAP net income decreased 25.3% over the same period in the prior year.
  • GAAP diluted EPS decreased 26.2%, primarily driven by the $110.5 million bargain purchase gain recognized in the prior-year quarter related to the Nevro acquisition.
  • U.S. net sales increased 3.0%, below international net-sales growth of 18.0% as reported.

What to watch

  • Delivery against reaffirmed full-year 2026 revenue guidance of $3.18 billion to $3.22 billion.
  • Delivery against updated full-year 2026 non-GAAP fully diluted EPS guidance of $4.95 to $5.05.
  • Whether adjusted gross margin expansion, operating leverage, and synergy realization continue.
  • U.S. net-sales growth and the stated US Spine share gains.
  • The contribution from Nevro, given management's cited 9% base-business revenue growth excluding Nevro.

Analysis

Globus Medical reported worldwide net sales of $789.6 million, up 5.9% as reported and 5.6% on a constant currency basis. The release described 9% base-business revenue growth excluding Nevro. Geographic performance was uneven: U.S. net sales increased 3.0%, while international net sales increased 18.0% as reported and 16.2% on a constant currency basis.

Management identified share gains across a majority of underlying businesses as the principal demand driver. US Spine grew 7%, and International Spine grew 14% as reported and 12% on a constant currency basis. The Company characterized US Spine as its fifth consecutive quarter of above-market revenue growth and cited continued strength across its product portfolio.

Profitability diverged sharply between GAAP and non-GAAP results. GAAP net income was $151.6 million, down 25.3%, while GAAP diluted EPS was $1.10, down 26.2% from $1.49. The release attributed the GAAP declines primarily to a $110.5 million bargain purchase gain tied to the Nevro acquisition that was recognized in the prior-year quarter. Non-GAAP diluted EPS was $1.34, up 55.8% from $0.86, alongside 200 basis points of adjusted gross margin expansion.

The Company reaffirmed full-year 2026 revenue guidance of $3.18 billion to $3.22 billion and raised non-GAAP fully diluted EPS guidance to $4.95 to $5.05 from $4.70 to $4.80. Management linked the earnings outlook to margin expansion, operating leverage, and synergy realization. The primary reported items to monitor are the pace of U.S. net-sales growth, continuation of international and spine growth, and whether the stated margin and synergy benefits support the higher non-GAAP EPS range.

Management, verbatim

Momentum continued into the second quarter with 6% overall revenue growth, or 9% growth excluding Nevro, driven by share gains across a majority of our underlying businesses, most notably US Spine, growing 7% and International Spine, growing 14% as-reported and 12% on a constant currency basis.

Keith Pfeil, President and Chief Executive Officer

US Spine, again, led the way in growth for the organization, marking our fifth straight quarter of above-market revenue growth, with continued strength across our entire product portfolio.

Kyle Kline, Chief Financial Officer

The strength of our second-quarter performance reflects disciplined execution across the business, including margin expansion, operating leverage, and synergy realization, which position us to deliver sustained earnings growth, and enhanced shareholder returns throughout the year.

Kyle Kline, Chief Financial Officer

Not in the filing

stated, not guessed
  • Prior-year worldwide net sales dollars.
  • U.S. net sales dollars and prior-year U.S. net sales dollars.
  • International net sales dollars and prior-year international net sales dollars.
  • Revenue dollars for US Spine and International Spine.
  • GAAP gross profit and GAAP gross margin.
  • Non-GAAP gross profit and non-GAAP gross margin value.
  • GAAP operating income or loss.
  • Non-GAAP operating income or loss.
  • Non-GAAP net income.
  • Non-GAAP Adjusted EBITDA.
  • Operating cash flow.
  • Free cash flow.
  • Capital expenditures.
  • Cash and cash equivalents.
  • Debt and other balance-sheet data.
  • Share repurchases.
  • Dividends.
  • Prior-quarter comparisons for reported metrics.
  • Full-year 2026 gross-margin, operating-expense, and tax-rate guidance.
  • Previous-release outlook needed for formal actual-versus-prior-guidance comparisons.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about GMED earnings dates

When is Globus Medical's next earnings date?
AlphAI has no date for GMED yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.